Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2023-11-13 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
募集资金管理制度
Capital/Financing Update Classification · 95% confidence The document is titled '江苏德源药业股份有限公司募集资金管理制度' which translates to 'Jiangsu Deyuan Pharmaceutical Co., Ltd. Fundraising Capital Management System'. It details the company's internal policies and procedures for managing and using funds raised through securities issuance. The document includes sections on the legal basis, storage, usage, changes, supervision, and reporting of raised funds. It references board meetings and shareholder approvals related to fundraising management. There is no indication that this is a financial report like an annual or interim report, nor is it an announcement of voting results or a proxy statement. It is a detailed governance document about fundraising capital management, which fits best under the category of Capital/Financing Update (CAP) as it relates to fundraising activities and capital management policies. The document length is over 6,000 characters and contains substantive content, not just an announcement or certification. Therefore, the classification is CAP with high confidence.
2023-11-13 Chinese
董事、监事换届公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the change and nomination of the company's board of directors and supervisors. It details the nomination of new directors and supervisors, their qualifications, and the procedural compliance with relevant laws and company regulations. There is no financial data, earnings information, or report publication mentioned. The content focuses on management and board changes, which fits the category of Board/Management Information (MANG). The document length is 3700 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is MANG.
2023-11-13 Chinese
关于召开2023年第三次临时股东大会通知公告（提供网络投票）
Regulatory Filings Classification · 95% confidence The document is a notice announcing the convening of the 2023 third extraordinary general meeting of shareholders (临时股东大会) for Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), agenda items such as election of board members and supervisors, amendments to company management systems, and related procedural information. It does not contain financial statements or results, nor is it a transcript or presentation. It is not a report but an announcement of a shareholder meeting and its agenda. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting itself rather than solicitation materials or voting results, it is best classified as a Regulatory Filing (RNS) as a general regulatory announcement about the shareholder meeting. The document length is under 5,000 characters, and it is a formal announcement of the meeting, not the meeting materials or results. Hence, Regulatory Filings (RNS) is the most appropriate classification.
2023-11-13 Chinese
2023年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 second extraordinary general meeting of shareholders of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes information about the meeting date, location, attendance, voting results on various proposals, and legal opinions confirming the legality and validity of the meeting and resolutions. The content focuses on shareholder meeting decisions and voting outcomes rather than financial results, management changes, or other report types. The document length is 2557 characters, which is relatively short but contains substantive voting results and meeting details, not just a notice or announcement of a report. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-11-12 Chinese
国浩律师（南京）事务所关于江苏德源药业股份有限公司2023年第一次临时股东大会之法律意见书
Regulatory Filings
2023-11-12 Chinese
[临时公告]德源药业:公司章程
Governance Information Classification · 100% confidence The document is titled "江苏德源药业股份有限公司章程" which translates to "Articles of Association of Jiangsu Deyuan Pharmaceutical Co., Ltd." It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, share transfer restrictions, shareholder meetings, and governance rules. It references relevant laws and regulations such as the Company Law of the People's Republic of China and securities laws. The content is a comprehensive governance document outlining the internal rules and structure of the company rather than a financial report, announcement, or other filing types. This matches the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is substantial (15,000 characters), indicating it is the full text of the governance document, not just an announcement or summary. Therefore, the appropriate classification is CGR with high confidence.
2023-11-12 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.